Polaris Pharmaceuticals
Shaw T. Chen worked as the Chief Executive Officer at Polaris Pharmaceuticals starting in March 2014. Prior to this, they held the position of Deputy Director, ODE-IV, CDER at FDA from November 1987 to February 2014.
Shaw T. Chen completed their education in a linear progression, starting with their undergraduate studies. From 1971 to 1977, they pursued a Doctor of Philosophy (Ph.D.) in Biophysical Chemistry at The Johns Hopkins University. Following this, from 1978 to 1980, they continued their education at Yale University as a Postdoctoral Fellow, specializing in Biophysical Chemistry. Finally, from 1980 to 1982, Shaw T. Chen attended the University of Miami Miller School of Medicine, where they earned their Doctor of Medicine (M.D.) degree.
Polaris Pharmaceuticals
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.